Business context and reporting period
This is CF Finance Acquisition Corp. III’s unaudited Form 10-Q for the quarter and six months ended June 30, 2021—not AEye, Inc.’s operating-company financial statements. CF Finance was a shell SPAC seeking a business combination; it reported no operations or operating revenue. Its proposed merger with AEye was pending, subject to stockholder approval and other closing conditions. The filing states that the company intended to change its name to AEye, Inc. at closing.
Key financial metrics
| Metric | Period or date | Value |
|---|---|---|
| Revenue | Three and six months ended June 30, 2021 | No operating revenue |
| Net loss | Three months ended June 30, 2021 | $1.91 million |
| Net loss | Six months ended June 30, 2021 | $1.57 million |
| Cash from operations | Six months ended June 30, 2021 | $(5,000) |
| Cash from investing activities | Six months ended June 30, 2021 | $(2.29) million |
| Cash from financing activities | Six months ended June 30, 2021 | $2.43 million |
| Operating cash | June 30, 2021 | $128,719 |
| Trust Account | June 30, 2021 | $232.31 million |
| Working capital deficit | June 30, 2021 | Approximately $3.16 million |
| Sponsor loans outstanding | June 30, 2021 | Approximately $3.46 million |
| Warrant liability | June 30, 2021 | $12.61 million |
Margins are not meaningful because the SPAC had no revenue. The quarterly loss primarily reflected a $1.57 million expense from the change in warrant fair value, alongside general and administrative, franchise tax, and related-party administrative expenses. Six-month interest income was $11,487; it was used to pay taxes.
Material changes versus the prior comparable period
The 2020 comparative periods showed no income or expenses, as the IPO had not yet occurred. Compared with December 31, 2020, operating cash increased from $1,250 to $128,719, while the working capital deficit widened from approximately $46,000 to $3.16 million. Sponsor loans rose from approximately $428,000 to $3.46 million, including $2.30 million used to fund a four-month deadline extension. Trust assets increased from $230.00 million to $232.31 million. The warrant liability increased from $12.06 million to $12.61 million.
Outlook, risks and unusual items
- Merger and financing: The proposed AEye combination included a $225 million PIPE commitment for 22.5 million shares at $10 per share, contingent on closing. The filing does not establish that the merger or PIPE would close.
- Deadline and liquidity: The SPAC’s deadline was extended to September 17, 2021, with a possible further extension to January 17, 2022 and additional extensions subject to sponsor funding. Management said available working capital and sponsor borrowing capacity were expected to cover needs through the earlier of a business combination or one year from the report date. Failure to complete a combination by the applicable deadline would require liquidation; warrants could expire worthless.
- Contingent fee: A $8.65 million fee to Cantor Fitzgerald, an affiliate of the sponsor, was payable upon completion of the business combination.
- Going concern: The filing discusses uncertainty tied to the business-combination deadline and sponsor support. The financial statements contain no adjustments for a possible failure to continue as a going concern.
- Controls: Management concluded disclosure controls were ineffective due to a material weakness connected to the prior-year financial-statement restatement. Remediation steps were underway but had not been fully evidenced; management believed remediation could occur during 2021.
- Other risks: Management said the COVID-19 pandemic could affect the company’s financial position, operations, or target search, but its impact was not determinable. The filing reported no legal proceedings and no material changes to previously disclosed risk factors.
Most important facts for investors to verify
- Confirm the merger’s final status, closing conditions, vote results, and the PIPE’s funded amount; this filing covers the SPAC, not AEye’s standalone performance.
- Check the applicable business-combination deadline and whether further extensions were funded.
- Review the latest liquidity, sponsor-loan balances, redemption levels, and any resulting dilution.
- Assess progress in remediating the material weakness and the effects of warrant-liability fair-value changes.
- Verify the contingent $8.65 million marketing fee and other transaction costs in the final merger disclosures.